CRISPR and Gene Editing Ethics

AOver the past decade, advances in biotechnology have fundamentally altered the boundaries of what science can achieve. Among the most significant of these developments is CRISPR-Cas9, a molecular tool that allows researchers to edit DNA sequences with remarkable precision. Originally derived from a natural defence mechanism found in bacteria, this technology has since been adapted for use in human medicine, agriculture, and biological research. Scientists have argued that CRISPR could potentially eliminate hereditary diseases that have affected millions of families across generations. Consequently, governments, research institutions, and international health bodies have begun to scrutinise not only the technical capabilities of this tool but also the profound ethical questions it raises.

BThe medical applications of CRISPR appear to be among its most promising features. Clinical trials conducted in recent years have demonstrated that gene editing may correct certain blood disorders, such as sickle cell disease and beta-thalassaemia, by modifying the patient's own stem cells. In theory, if a faulty gene responsible for a debilitating condition were replaced with a functional copy, the patient could be permanently cured. Furthermore, researchers have suggested that CRISPR-based therapies might eventually target cancerous cells with far greater accuracy than conventional chemotherapy, thereby reducing harmful side effects. Given that these diseases impose significant burdens on healthcare systems in developing nations, including Bangladesh, the potential benefits are difficult to dismiss.

CNevertheless, the technology's capacity to modify the human germline — that is, changes made to embryos that would be inherited by future generations — has provoked considerable controversy. In 2018, a Chinese scientist announced the birth of twin girls whose embryos had been gene-edited to confer resistance to HIV, an act that was widely condemned by the international scientific community. Critics argued that such modifications were premature, ethically unjustifiable, and potentially dangerous, given that the long-term consequences of heritable gene edits remain largely unknown. Regulatory frameworks in most countries currently prohibit germline editing for reproductive purposes, though the enforcement of such policies varies considerably across jurisdictions.

DIn contrast to the concerns surrounding germline editing, somatic gene therapy — which targets non-reproductive cells in living individuals — is generally regarded as more ethically acceptable. Since somatic edits affect only the individual being treated and are not passed on to offspring, many bioethicists consider them analogous to conventional medical interventions. However, access and equity present a serious challenge. CRISPR-based treatments have already been approved in some high-income countries at costs exceeding one million dollars per patient. This economic reality suggests that, without deliberate policy intervention, the benefits of gene editing may remain the exclusive preserve of wealthy nations and privileged individuals, thereby widening existing global health inequalities.

EThe ethical governance of CRISPR technology therefore requires a balanced and internationally coordinated approach. Scientific progress must not be halted unnecessarily, as doing so could deprive future generations of life-saving treatments. At the same time, regulatory bodies must ensure that innovation does not outpace ethical scrutiny. It has been proposed that an international oversight committee, similar in structure to the frameworks governing nuclear technology, could monitor gene editing research and establish binding global standards. Whether such cooperation is achievable in a world of competing national interests remains to be seen. What appears certain, however, is that the decisions made today regarding the governance of CRISPR will shape the trajectory of human health and identity for centuries to come.